News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic
Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the market, as the drugmaker expects to submit the drug for approval for weight loss by the end of the year.
Clinical Trials Arena on MSN1d
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trialLilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application ...
Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...
Asian News International on MSN6h
Lilly's orforglipron consistent with injectable GLP-1 medicines in Phase 3 trialAccording to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback